These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 17639666

  • 1. [What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?].
    Egli M, Ruiz J.
    Rev Med Suisse; 2007 Jun 06; 3(114):1449-50, 1453-5. PubMed ID: 17639666
    [Abstract] [Full Text] [Related]

  • 2. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb 06; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar 06; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 5. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Mar 06; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb 06; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 7. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
    Mannucci E, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Nov 06; 18(9):639-45. PubMed ID: 18849155
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
    Efendic S, Alvarsson M, Brismar K, Wagner H.
    Acta Physiol (Oxf); 2008 Jan 06; 192(1):117-25. PubMed ID: 18171434
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Metformin role in the treatment of type 2 diabetes in 2008].
    Spada A, Philippe J.
    Rev Med Suisse; 2008 Jun 04; 4(160):1392-4, 1396-7. PubMed ID: 18630062
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
    Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K.
    Expert Opin Investig Drugs; 2009 Oct 04; 18(10):1495-503. PubMed ID: 19758106
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J, Faust M.
    Dtsch Med Wochenschr; 2008 Oct 04; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract] [Full Text] [Related]

  • 18. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX.
    Postgrad Med; 2008 Jul 04; 120(2):5-17. PubMed ID: 18654064
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
    Rosenstock J, Zinman B.
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr 04; 14(2):98-107. PubMed ID: 17940427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.